Aardvark Therapeutics Reports Q2 2026 Financial Results

What Happened
Aardvark Therapeutics, Inc. announced and filed an 8-K on August 11, 2026 reporting its financial results for the quarter ended June 30, 2026 and providing business updates. The company furnished the full press release as Exhibit 99.1 to the Current Report on Form 8-K.

Key Details

• Filing date: August 11, 2026 (Form 8-K).
• Reporting period: Quarter ended June 30, 2026 (second quarter 2026).
• Disclosure: Press release with results and business updates furnished as Exhibit 99.1.
• Filing signed by CEO Tien‑Li Lee, M.D.

Why It Matters
This 8-K delivers Aardvark’s latest quarterly results and operational updates outside the regular 10-Q cycle; investors should review the Exhibit 99.1 press release for specific earnings, revenue, cash position, guidance or program updates. Those details are material for evaluating the company’s near-term financial health and progress on its business objectives.